Home › announces study
 

Keywords :   


Tag: announces study

PsiOxus Therapeutics Announces Positive Study Results of Oncolytic...

2014-06-03 13:42:23| Logistics - Topix.net

OXFORD, England & CHICAGO -- -- PsiOxus Therapeutics, Ltd. , an award-winning biotechnology company developing innovative, novel treatments for cancer, announced that updates for its on-going international multicentre clinical program of the oncolytic vaccine enadenotucirev were presented at the 2014 American Society of Clinical Oncology Annual ... (more)

Tags: results study positive announces

 

Biodesix Announces Publication of Seminal PROSE Study in The Lancet Oncology

2014-05-21 23:09:05| Logistics - Topix.net

PROSE is the first successful, prospective biomarker-stratified study in thoracic oncology to test treatment and biomarker interaction.

Tags: study publication announces oncology

 
 

Biodesix Announces Publication of Seminal PROSE Study in The Lancet Oncology

2014-05-13 03:29:48| Logistics - Topix.net

PROSE is the first successful, prospective biomarker-stratified study in thoracic oncology to test treatment and biomarker interaction.

Tags: study publication announces oncology

 

Gilead Announces Results from Phase 2 Study Showing Reduction in...

2014-05-11 00:54:46| Biotech - Topix.net

Gilead Sciences, Inc. today announced results from HARMONY, a randomized, double-blind, placebo-controlled Phase 2 study evaluating the effect of ranolazine and low-dose dronedarone, each given alone and in combination, on atrial fibrillation burden in patients with paroxysmal atrial fibrillation .

Tags: in results showing study

 

Merck Announces Results from Phase 2b Study of MK-8237, an Investigational House Dust Mite Sublingual Allergen Immunotherapy Tablet

2014-03-04 23:30:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. Data Presented at the 2014 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a Phase 2b study evaluating two doses of its investigational house dust mite sublingual immunotherapy tablet (MK-8237). The data were presented for the first time during a late-breaking oral session at the 2014 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) in San Diego. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orRobert Consalvo, 908-423-6595orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: results house study phase

 

Sites : [1] [2] [3] [4] [5] next »